33776291|t|Neuroleptic malignant syndrome associated with the use of injection zuclopenthixol acetate.
33776291|a|Zuclopenthixol is available in two parenteral formulation,i.e., in the form of acetate and decanoate. It has high affinity for dopamine D1 and D2 receptors. There is limited literature of association of neuroleptic malignant syndrome with the use of zuclopenthixol monotherapy. These case reports have mostly implicated zuclopenthixol decanoate, and also zuclopenthixol acetate. In this report, we present a case of neuroleptic malignant syndrome associated with use of zuclopenthixol acetate.
33776291	0	30	Neuroleptic malignant syndrome	Disease	MESH:D009459
33776291	68	90	zuclopenthixol acetate	Chemical	MESH:C060342
33776291	92	106	Zuclopenthixol	Chemical	MESH:D003006
33776291	171	178	acetate	Chemical	MESH:D000085
33776291	183	192	decanoate	Chemical	MESH:D003651
33776291	219	247	dopamine D1 and D2 receptors	Gene	1812;1813
33776291	295	325	neuroleptic malignant syndrome	Disease	MESH:D009459
33776291	342	356	zuclopenthixol	Chemical	MESH:D003006
33776291	412	436	zuclopenthixol decanoate	Chemical	MESH:C029674
33776291	447	469	zuclopenthixol acetate	Chemical	MESH:C060342
33776291	508	538	neuroleptic malignant syndrome	Disease	MESH:D009459
33776291	562	584	zuclopenthixol acetate	Chemical	MESH:C060342
33776291	Positive_Correlation	MESH:D003006	MESH:D009459
33776291	Association	MESH:D003006	1813
33776291	Positive_Correlation	MESH:C060342	MESH:D009459
33776291	Association	MESH:D003006	1812

